A new patient-friendly test for anal cancer screening
This project unites experts from public and private partners to develop a new test for detecting anal cancer and its precursors. The test uses simple anal swabs to analyze changes in DNA methylation, offering a patient-friendly alternative to current costly and invasive screening methods. This public-private partnership aims to improve screening access and outcomes for high-risk groups, such as HIV-positive men who have sex with men.
Anal cancer rates are rising, with HIV-positive men who have sex with men facing the highest risk. Existing screening methods are expensive, uncomfortable, and scarce, leading to many at-risk individuals being under-screened or even unscreened. Early detection of anal precancer is crucial because timely treatment can prevent progression to cancer, improving survival and quality of life. This project addresses this urgent health issue by developing a more accessible and effective screening approach
The project involves collecting anal swabs from high-risk individuals and analyzing over 850,000 potential DNA methylation markers to find those linked to anal precancer and anal cancer. From these, researchers identify the most promising markers to create a test that reliably distinguishes between high and low cancer risk. This test avoids immediate invasive procedures, making it less burdensome and easier to screen larger populations at risk of anal cancer.
The main deliverable is a DNA methylation test applicable to anal swabs that can identify patients at risk of anal (pre)cancer risk that need referral for high resolution anoscopy. The test avoids unnecessary referral of patients with a negligible cancer risk. Future steps include clinical validation and expanding validation to other at-risk groups, such as HIV-positive women and women with vulvar or cervical (pre)cancer. Ultimately, this innovation aims to offer broad, accessible screening to improve early diagnosis and prevention and to reduce the impact of anal cancer on society.
This project brought together experts from public and private partners to develop a new test for detecting anal cancer and its precursors. Using simple anal swabs to analyze changes in DNA methylation, the test offers a patient-friendly alternative to current costly and invasive screening methods. This public-private partnership aimed to improve screening access and outcomes for high-risk groups, especially HIV-positive men who have sex with men.
Anal cancer rates are rising, with HIV-positive men who have sex with men at highest risk. Existing screening methods are expensive, uncomfortable, and limited in availability, causing many at-risk individuals to be under-screened. Early detection of anal precancer is essential because treatment could prevent progression to cancer, improving survival and quality of life. This project addressed this growing health concern by innovating screening approaches to reach more people effectively and affordably.
Anal swabs were collected from high-risk individuals and analyzed for over 850,000 potential DNA methylation markers to identify those linked to anal precancer and cancer. By selecting the most promising markers, a multiplex PCR-based test targeting the optimal 3-gene classifier and a reference gene was developed that could reliably distinguish between patients with a high and a low cancer risk. This test reduces the need for invasive examination in low-risk patients, making screening easier and less burdensome for patients and healthcare providers.
